CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma
The Efficacy and Safety of CM082 Combined With Everolimus in Chinese Patients With Metastatic Renal Cell Carcinoma: a Randomized, Double-blind, Double Dummy, Multicenter Study
Sponsor: AnewPharma
This PHASE3 trial investigates Renal Cell Cancer Metastatic and is currently ongoing. AnewPharma leads this study, which shows 9 recorded versions since 2016 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE3
Status: Unknown Status → Unknown
-
Mar 2023 — Jul 2024 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
-
Mar 2021 — Mar 2023 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting · Phase: PHASE2_PHASE3 → PHASE3
-
Jan 2021 — Mar 2021 [monthly]
Recruiting PHASE2_PHASE3
▶ Show 4 earlier versions
-
Mar 2019 — Jan 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Jun 2018 — Mar 2019 [monthly]
Recruiting PHASE2_PHASE3
-
Dec 2017 — Jun 2018 [monthly]
Recruiting PHASE2_PHASE3
Status: Not Yet Recruiting → Recruiting
-
May 2017 — Dec 2017 [monthly]
Not Yet Recruiting PHASE2_PHASE3
First recorded
Dec 2016
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- AnewPharma
For direct contact, visit the study record on ClinicalTrials.gov .